Related Experiment Video

Updated: Jun 5, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Mathematical modelling of hepatitis C treatment for injecting drug users

Natasha K Martin1, Peter Vickerman, Matthew Hickman

  • 1Department of Social Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK. natasha.martin@bristol.ac.uk

Journal of Theoretical Biology
|January 18, 2011
PubMed

Insights

Antiviral treatment can control or eradicate Hepatitis C virus (HCV) among injecting drug users (IDUs). Mathematical modeling shows treatment levels needed depend on injecting duration and infection risk, not immunity.

Area of Science:

  • Epidemiology
  • Mathematical Modeling
  • Public Health

Background:

  • Hepatitis C virus (HCV) is a significant cause of liver disease, primarily transmitted among injecting drug users (IDUs) in developed nations.
  • Despite effective treatments, active IDUs are undertreated due to concerns about reinfection.
  • Current mathematical models often use treatment functions proportional to the infected population, differing from fixed yearly treatment targets in policy.

Purpose of the Study:

  • To develop a mathematical model simulating HCV transmission dynamics among active IDUs.
  • To evaluate the impact of antiviral treatment strategies on HCV control and eradication.
  • To compare the effects of two treatment approaches: treating a proportion versus a fixed number of infected individuals annually.

Main Methods:

  • Development of a mathematical model for HCV transmission within the active IDU population.
  • Analysis of two distinct treatment functions: proportional and fixed number.
  • Calculation of analytical solutions for treatment thresholds required for disease clearance or control.
  • Sensitivity analysis to identify key parameters influencing the critical treatment level.

Main Results:

  • Different treatment models exhibit distinct bifurcation behaviors.
  • Achievable treatment levels can lead to HCV control or eradication across various prevalence rates.
  • Injecting duration and infection risk are the most critical parameters determining the required treatment level.
  • Immunity status (presence or absence) does not significantly alter the treatment threshold.

Conclusions:

  • Mathematical modeling supports the feasibility of using antiviral treatment as a prevention strategy to reduce HCV spread among IDUs.
  • The study highlights the importance of considering specific treatment implementation strategies (proportional vs. fixed) in public health policy.
  • Targeted interventions focusing on high-risk behaviors and durations can optimize treatment efforts for HCV elimination in IDU populations.

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.